Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 13, 2015 6:55 AM EDTHACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 13, 2015 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2015.
"We continue to advance BrainStorm's lead program, NurOwn®, for the treatment of amyotrophic lateral sclerosis," stated Dr. Tony Fiorino, BrainStorm's CEO. "We announced earlier this week the completion of patient enrollment in our randomized, double-blind,... More
